期刊文献+

乳腺癌术后化疗不良反应的临床特点 被引量:1

Exploration on clinical characteristics of adverse reactions in postoperative chemotherapy of breast cancer
原文传递
导出
摘要 目的探讨分析乳腺癌术后化疗常见的不良反应特点。方法选取2011年1月至2014年1月经手术治疗后伴有浸润性乳腺癌的68例患者,按照随机数表法分为观察组和对照组。观察组为AC→T方案化疗,对照组为TAC方案化疗。比较两组患者化疗前1 d、化疗后7 d免疫功能、血象及细胞因子变化、化疗后的不良反应及其临床特点。结果化疗后观察组的CD4+、CD8+、CD4+/CD8+水平明显高于对照组,差异均有统计学意义[(43.22±2.76)%vs(37.32±1.78)%、(42.45±4.32)%vs(34.22±3.26)%、(1.96±0.35)vs(1.43±0.42),均P<0.000 1],免疫球蛋白Ig A、Ig G、Ig M水平明显低于对照组[(1.25±0.11)g/L vs(2.01±0.26)g/L、(8.21±1.22)g/L vs(11.34±2.33)g/L、(1.24±0.21)g/L vs(1.76±0.34)g/L,均P<0.000 1]。观察组患者的PLT、WBC、IL-4、IL-10水平明显高于对照组,分别为(175±24)×109/L vs(159±25)×109/L、(8.43±2.42)×109/L vs(7.11±1.78)×109/L、(46.32±4.22)U/ml vs(34.21±3.87)U/ml、(34.21±4.21)U/ml vs(25.45±3.87)U/ml(P=0.009、0.013、<0.000 1、<0.000 1)。观察组的中性粒细胞减少与减少性的中性粒细胞发热的不良反应发生率分别为44.12%、26.47%,明显比对照组低(79.41%、64.71%),差异有统计学意义(χ2=8.967、10.019,P=0.003、0.002)。结论乳腺癌术后采取不同化疗方案均存在不良反应,然而大多数为Ⅲ度以下的不良反应,并均能耐受,予以有效的处理后不良反应有所好转。 Objective To analyze the characteristics of adverse reactions in postoperative chemotherapy of breast cancer. Methods Sixty-eight patients of invasive breast cancer treated in Breast Disease Treatment Center of Chongqing Institute of Cancer from January 2011 to January 2014 were randomly divided into observation group and control group. The observation group were treated with AC→T regimen, and the control group with TAC regimen. Immune function, blood and cytokine level changes 1 day before and 7 days after chemotherapy were compared. After chemotherapy, adverse reactions and clinical characteristics of the two groups were observed. Results After chemotherapy, CD4+, CD8+, CD4+/CD8+ of the observation group were significantly higher than control group [(43.22 ± 2.76)% vs (37.32 ± 1.78)%, (42.45 ± 4.32)%vs (34.22 ± 3.26)%, (1.96 ± 0.35) vs (1.43 ± 0.42), all P〈0.000 1]. Immunoglobulin IgA, IgG, IgM levels of observation group were significantly lower than control group respectively [( 1.25 ± 0.11) g/L vs (2.01±0.26) g/L、(8.21±1.22) g/L vs (11.34±2.33) g/L, (1.24±0.21) g/L vs (1.76±0.34) g/L, all P〈0.000 1]. PLT, WBC, IL-4, IL-10 levels of observation group were significantly higher than control group [(175±24)×109/L vs (159±25)×109/L、(8.43±2.42)×109/L vs (7.11±1.78)×109/L、(46.32±4.22) U/ml vs (34.21± 3.87) U/ml、(34.21 ± 4.21) U/ml vs (25.45 ± 3.87) U/ml, P=0.009、0.013、〈0.000 1、〈0.000 1]. The adverse reaction rates of fever with neutropenia and reduction were 44.12% and 26.47%, lower than the control group (x2=8.967, 10.019, P=0.003, 0.002). Conclusion The cancer patients taking chemotherapy have different adverse reactions, most of which are below degree Ⅲ, well tolerated, and can be improved after treatment.
作者 刘玲 曹鑫
出处 《中华普通外科学文献(电子版)》 2016年第3期209-212,共4页 Chinese Archives of General Surgery(Electronic Edition)
关键词 乳腺肿瘤 药物疗法 联合 Breast neoplasmas Drug therapy,combination
  • 相关文献

参考文献15

二级参考文献116

  • 1中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417. 被引量:268
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3王佳,蒋晓莲.乳腺癌改良根治术后病人的心理护理[J].护理研究(上旬版),2007,21(1):18-19. 被引量:28
  • 4Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 -year survival: an overview of the randomised trials[J]. Lancet, 2005, 365(9472) : 1687 - 1717.
  • 5JONES S, HOLMES F A, O' SHAUGHNESSY J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7 - Year Follow - Up of US Oncology Research Trial 9735 [ J]. J Clin Oncol, 2009, 27(8) : 1177 -1183.
  • 6VALERO V. Docetaxel and cyclophosphamide in patients with ad- vanced solid tumors [ J ]. Oncology ( Williston Park), 1997,11 ( 6 Suppl 6) : 21 -23.
  • 7GOLDSTEIN L J, O'NEILL A, SPARANO J A, et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Inter- group Triat E 2197[J]. J Clin Oncol, 2008, 26(25): 4092 - 4099.
  • 8TAKABATAKE D, TAIRA N, HARA F, et al. Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients [ J ]. Jpn J Clin Oncol, 2009, 39 (8) : 478 -483.
  • 9CHAN A, FU W H, SHIH V, et al. Impact of colony - stimula- ting factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy [J]. Support Care Cancer, 2011, 19(4) : 497 -504.
  • 10VIANI G A, AFONSO S L, STEFANO E J, et al. Adjuvant tras- tuzumab in the treatment of her - 2 - positive early breast cancer : a meta - analysis of published randomized trials [ J ]. BMC Canc- er, 2007, 7: 153.

共引文献119

同被引文献14

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部